Real-world data is helping to fine-tune care decisions for multiple myeloma patients: New research published at 2024 ASCO Annual Meeting
Researchers and clinicians agree that standards of care should be regularly reviewed and optimized based on the latest evidence to ensure that existing recommendations remain relevant.
Exploring standards of care in real-world settings with RWD
Real-world data (RWD) can help to illuminate patterns in therapy selection and the correlation to outcomes, giving oncologists and researchers some additional guidance on emerging trends in the oncology community.
From Data to Discovery: How AI Is Accelerating Progress in Oncology
the latest wave of data, technology, and artificial intelligence (AI) advances are challenging views, empowering individuals across life sciences functions to answer research questions using many different types of RWD
How COTA & Komodo Health Combine Real-World Datasets for Better Patient Insights
Komodo Health and COTA teamed up to link COTA’s high-quality oncology data with Komodo’s vast Healthcare MapTM
Getting personal with real-world data at ViVE 2024
At ViVE 2024 in Los Angeles, COTA’s Chief Medical Officer, C.K. Wang, MD will take part in a discussion session called “Data That’s Getting Personal”.
LLMs aren’t good enough at diagnostics yet. What will it take to get them there?
Large language models (LLMs) are the foundation of highly hyped generative AI tools like Chat-GPT and Google Bard.
How Real-World Data Helps Explore Alternative Dosing for Colorectal, Pancreatic Cancer Therapy
Research from MedStar Georgetown Lombardi Comprehensive Cancer Center and COTA shows the potential of a more patient-friendly dosing regimen for Stage 4 CRC/PC or locally advanced PC.
This collaboration highlights how real-world data can contribute to clinical research and can help answer pressing questions about care already taking place in clinical practice.
Key Takeaways from ASH 2022: Real-World Data Gets Down to Business
The American Society of Hematology’s 2021 annual meeting showed that real-world data is no longer the new kid on the block – it’s an indispensable part of the toolkit for therapeutic development and clinical research. COTA is proud to be a part of the discussion, contributing research this year for chronic lymphocytic leukemia.
Are Pharma Companies Ready to Harness the Promises of Real-World Data?
Partnering with Impatient Health, we take a comprehensive look at the realities of real-world data and the challenges that pharma companies face in leveraging it to gain actionable insight, based on feedback from executives at well-known, major pharma companies.
This is a key part of our mission to provide the most comprehensive cancer care possible by leveraging the latest advances in data science and technology.
The Power of Collaboration: ASH Showcases COTA’s Real World Data and Research at Annual Meeting
COTA is honored to have contributed to three abstracts accepted for poster presentation at the American Society of Hematology’s 64th Annual Meeting, which cover a range of hematologic cancers. These studies focus on patient- and clinician-reported performance status in Multiple Myeloma, and real-world treatment patterns among patients with newly diagnosed Acute Myeloid Leukemia in the US.
